Insider Trading Alert - CI, SHOO And NXTM Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Friday, May 15, 2015, 111 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $1,266.50 to $281,749,912.50.

Highlighted Stocks Traded by Insiders:

Cigna (CI) - FREE Research Report

Manders Matthew G, who is Pres. US Comm Mkts & Gbl HC Op at Cigna, sold 3,028 shares at $132.43 on May 15, 2015. Following this transaction, the Pres. US Comm Mkts & Gbl HC Op owned 47,799 shares meaning that the stake was reduced by 5.96% with the 3,028-share transaction.

The shares most recently traded at $132.45, up $0.02, or 0.02% since the insider transaction. Historical insider transactions for Cigna go as follows:

  • 4-Week # shares sold: 5,000
  • 12-Week # shares sold: 142,512
  • 24-Week # shares sold: 157,302

The average volume for Cigna has been 1.7 million shares per day over the past 30 days. Cigna has a market cap of $33.9 billion and is part of the health care sector and health services industry. Shares are up 28.12% year-to-date as of the close of trading on Friday.

Cigna Corporation, a health services organization, provides insurance and related products and services in the United States and internationally. The stock currently has a dividend yield of 0.03%. The company has a P/E ratio of 16.6. Currently, there are 8 analysts who rate Cigna a buy, no analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CI - FREE

TheStreet Quant Ratings rates Cigna as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, good cash flow from operations and solid stock price performance. We feel its strengths outweigh the fact that the company shows low profit margins. Get the full Cigna Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Steven Madden (SHOO) - FREE Research Report

Schwartz Thomas H., who is Director at Steven Madden, sold 5,397 shares at $39.01 on May 15, 2015. Following this transaction, the Director owned 8,997 shares meaning that the stake was reduced by 37.49% with the 5,397-share transaction.

The shares most recently traded at $39.16, up $0.15, or 0.39% since the insider transaction. Historical insider transactions for Steven Madden go as follows:

  • 4-Week # shares sold: 101,500
  • 12-Week # shares sold: 123,781
  • 24-Week # shares sold: 123,781

The average volume for Steven Madden has been 570,900 shares per day over the past 30 days. Steven Madden has a market cap of $2.5 billion and is part of the consumer goods sector and consumer non-durables industry. Shares are up 22.65% year-to-date as of the close of trading on Friday.

Steven Madden, Ltd. designs, sources, markets, and sells fashion-forward name brand and private label footwear for women, men, and children. The company has a P/E ratio of 22.6. Currently, there are 6 analysts who rate Steven Madden a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SHOO - FREE

TheStreet Quant Ratings rates Steven Madden as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels and solid stock price performance. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full Steven Madden Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

NxStage Medical (NXTM) - FREE Research Report

Swan Winifred L, who is SVP and General Counsel at NxStage Medical, sold 500 shares at $16.33 on May 15, 2015. Following this transaction, the SVP and General Counsel owned 29,359 shares meaning that the stake was reduced by 1.67% with the 500-share transaction.

The shares most recently traded at $16.63, up $0.30, or 1.8% since the insider transaction. Historical insider transactions for NxStage Medical go as follows:

  • 4-Week # shares bought: 10,150
  • 4-Week # shares sold: 1,000
  • 12-Week # shares bought: 10,150
  • 12-Week # shares sold: 5,500
  • 24-Week # shares bought: 10,150
  • 24-Week # shares sold: 21,500

The average volume for NxStage Medical has been 479,500 shares per day over the past 30 days. NxStage Medical has a market cap of $1.1 billion and is part of the health care sector and health services industry. Shares are down 7.14% year-to-date as of the close of trading on Friday.

NxStage Medical, Inc., a medical device company, develops, manufactures, and markets products for the treatment of kidney failure, fluid overload, and related blood treatments and procedures. Currently, there are 4 analysts who rate NxStage Medical a buy, 1 analyst rates it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on NXTM - FREE

TheStreet Quant Ratings rates NxStage Medical as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including deteriorating net income and disappointing return on equity. Get the full NxStage Medical Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you liked this article you might like

Snap and Coca-Cola Are Among 16 Stocks That Are Ready to Change Direction

Snap and Coca-Cola Are Among 16 Stocks That Are Ready to Change Direction

The Really Big Money Rushes to Super Bowl

The Really Big Money Rushes to Super Bowl

Big Pharma and the Sellers of Its Products Now Have a Problem

Big Pharma and the Sellers of Its Products Now Have a Problem

Managed Care Stocks Thrashed on Amazon News but Could Be Buying Opportunity

Managed Care Stocks Thrashed on Amazon News but Could Be Buying Opportunity

Can Buffett and a Couple of Rich Celebrity CEOs Really Fix Healthcare?

Can Buffett and a Couple of Rich Celebrity CEOs Really Fix Healthcare?